Nerol
CAS 106-25-2
Nerol (CAS 106-25-2) is a pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 555.1111111111111 ug.mL-1 | 9 | - |
| - | IC50 | 100000 nM | 3 | - |
| - | EC50 | 11700 nM | 1 | - |
| - | Potency | 3.5 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| NEROL | 2274605 | SU | MTHSPL |
| nerol | 2274605 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Nerol used for in pharmaceutical contexts?
Nerol (CAS 106-25-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Nerol?
No adverse-event association or SIDER side-effect rows are rendered for Nerol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Nerol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for NEROL with EU status "permitted".
What clinical phase is Nerol in?
No phase 1-4 clinical development badge is rendered for Nerol because the matched compound identifier rows do not contain a max-phase value.